trial · primary record
Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 333 |
| Primary completion | 2029-03-19 |
| Primary endpoint | Best Overall Response Rate (ORR) |
| Registry ID | NCT05963074 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:47.629Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05963074
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.